Assessing the Efficacy of Maropitant Versus Ondansetron in the Treatment of Dogs with Parvoviral Enteritis

J Am Anim Hosp Assoc. 2018 Nov/Dec;54(6):338-343. doi: 10.5326/JAAHA-MS-6650. Epub 2018 Oct 1.

Abstract

Antiemetics are commonly prescribed during the treatment of canine parvoviral enteritis. This blinded, randomized prospective study compared the quality of clinical recovery and duration of hospitalization in canine parvoviral dogs receiving either maropitant (1 mg/kg [0.45 mg/lb] IV q 24 hr, n = 11) or ondansetron (0.5 mg/kg [0.23 mg/lb] IV q 8 hr, n = 11). All dogs were treated with IV fluids, cefoxitin, and enteral nutrition. Frequency of vomiting and pain scoring were recorded twice daily. Rescue analgesics and antiemetics were administered as dictated by specific pain and vomiting criteria. Clinical severity scoring, body weight, and caloric intake were monitored daily. When comparing dogs receiving maropitant versus ondansetron, respectively, there were no differences in duration of hospitalization (3.36 ± 0.56 versus 2.73 ± 0.38 days, P = .36), requirement of rescue antiemetic (3/11 versus 5/11 dogs, P = .66), duration of vomiting (5 versus 4 days, P = .65), or days to voluntary food intake (2 versus 1.5 days, P = 1.0). Results of this study suggest that maropitant and ondansetron are equally effective in controlling clinical signs associated with parvoviral enteritis.

Publication types

  • Clinical Trial, Veterinary

MeSH terms

  • Animals
  • Dog Diseases / drug therapy*
  • Dogs
  • Enteritis / drug therapy
  • Enteritis / veterinary*
  • Ondansetron / therapeutic use*
  • Parvoviridae Infections / drug therapy
  • Parvoviridae Infections / veterinary*
  • Parvovirus, Canine
  • Prospective Studies
  • Quinuclidines / therapeutic use*
  • Random Allocation
  • Treatment Outcome

Substances

  • Quinuclidines
  • Ondansetron
  • maropitant